We have an established history of more than 10 years in Latin America. Mexico and Brazil account for almost 80% of the revenue generated in the region. Our expanded regional coverage gives us a presence Colombia, Chile, Ecuador, Costa Rica, Peru and Argentina. Our comprehensive product range encompasses in branded prescription and OTC products.
Contribution to Group revenue (%)
Revenue by segment (%)
- The Spanish Latin American private pharmaceutical sector grew 4.3% in value for the year to 31 August 2019 as compared to the prior period
- The Brazilian private pharmaceutical market declined 7% and was valued by IMS at USD28 billion for the year to 30 June 2019, negatively impacted by foreign exchange
Source: June 2019 IQVIA
Number of products launched:
In-market sales value of pipeline as at 30 June 2019 anticipated to be launched in:
0 – 2 years
3 – 5 years
Number of product recalls:
Average staff turnover*:
Number of work-related fatalities:
Number of permanent employees:
# The number of product launches has been restated to take into account discontinued operations.
^ Includes 468 employees transferred with the disposal of the Nutritionals business.
* Rate excludes employees transferred in Nutritionals disposal.
|Total||3 083||2 910||6|
|Regional Brands||2 114||2 001||6|
|Sterile Focus Brands||969||909||7|
Note: Commercial Pharmaceuticals revenue is disclosed by customer geography.